藥明康德廿二日宣佈，投資一千五百萬元，讓位於麻州劍橋市的子公司WuXi
NextCODE，和DNAnexus達成策略聯盟關係，進一步提高該公司在未來醫藥研發上的影響力，也展示出基因組學在全球市場上已成重要經濟推動力。
藥明康德是在昨（廿三）日落幕的 2015年生物資訊科技世界（ Bio-IT World）會議及展覽中，做此宣布。
該會議聚集了來自三十二個國家的三千多名生命科學，臨床診斷，醫療，以及資訊科技界專業人士，探討資訊科技可以如何改善生物醫療的研究，臨床診斷及醫療。
藥明康德總裁李革指出，藉著這投資一千五百萬元進DNAnexus的策略性投資及合夥關係，該公司將把全世界最好的科技，從世界上的任何角落，時間，提供給任何一家公司或機構，以充分發會基因組學分析及研發的能力。
藥明康德指WuXi NextCODE和DNAnexus這兩家公司攜手，將為基因組學提供一個全球性排台，製藥公司及診斷供應商可以在那兒儲存，詮釋序列數據，並經由單一雲端平台和全球各地的同僚合作。也讓他們得以把全球性的以雲端為基礎的基因組學平台，帶進中國
藥明康德是全球最大的製藥界服務公司之一，百分之九十的客戶來自美國。中國是世界上第二大藥物市場，全世界有25%的基因測序是在中國進行。
藥明康德今年二月才宣佈在劍橋市設據點，開分公司。沒多久之後就以六千五百萬元收購了位於劍橋市的 NextCODE公司，使得藥明康德的產業鏈更加健全。該公司指出，基因組學的發展迅速，數據量累積之快，也極為驚人。該公司雖有最尖端的基因分析能力，但無儲存機制，如今藥明康德投資，持有DNAnexus股份，他們就可從分析，儲存到再取用的擁有處理基因數據的完整能力，未來將有更多可能。
近年來，麻州已成世界各地製藥及醫藥研發公司的兵家必爭之地。來自中國的公司中，華大基因，藥明康德是最知名的兩家。
圖片說明：
WuXiNextCOD在2015年生物資訊科技世界（ Bio-IT World）會議及展覽中，擺了個小攤位。（菊子攝）
Now
available via a single platform are the sequence data analysis suite that has
analyzed more genomes than any other; pioneering Silicon Valley genomics cloud
technology; and global, open-access drug discovery and development capabilities
serving the life science industry:
•
Bringing cloud-based genomics to China and Chinese genomics to the world
•
Speeding the development and delivery of sequence-based diagnostics worldwide
•
Expanding research with collaborations and datasets of unprecedented scope and
size
•
Streamlining the development of personalized medicine and companion diagnostics
•
Leveraging WuXi’s leading genomics and R&D through DNAnexus’ global
cloud
“This
strategic investment and partnership bring together the world’s best
technologies to enable any company or institution to leverage the full power of
genomics and our R&D capabilities at any time, from anywhere,” commented Dr
Ge Li, Chairman and CEO of WuXi PharmaTech. “By connecting through a compliant
cloud everything from CLIA sequencing to drug discovery and development to companion
diagnostics, we are empowering clinicians, institutions and life science
companies to use genomics to benefit patients more globally and effectively
than ever before.”
“This
alliance with DNAnexus will fuel innovation across the science and business of
genomics, and make our collective capabilities even more valuable to the range
of our customers on four continents,” said Hannes Smarason, Chief Operating
Officer of WuXi NextCODE. “We see this transforming the way large-scale
sequence data is applied, underpinning virtual diagnostics enterprises,
breakthroughs in rare disease and the rapid advance of more targeted,
personalized medicine.”
“Our
customers are global in scope and we’re teaming with WuXi NextCODE to extend
the power and geographic reach of our cloud solution to support our partners’
efforts,” said Richard Daly, CEO of DNAnexus. “China has 20% of the world’s
sequencing capacity and is a pillar of cutting-edge science worldwide. The
DNAnexus platform enables research, drug development, and clinical diagnostic
testing worldwide, and this alliance and investment allows us to expand our
global network for genomic medicine.”
With
WuXi NextCODE’s unique genomic database model and clinical and research
interfaces directly available on the DNAnexus cloud, users will be able to
store and interpret their sequence data and collaborate with colleagues around
the world through one platform. The companies will also provide and host the
same platform and capabilities within China, in full compliance with local
regulations. Users will be able to use their genomic data seamlessly in tandem
with the open access capability and technology platform that WuXi offers to the
global pharmaceutical, biopharmaceutical and medical device industry.
沒有留言:
發佈留言